Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausal HR+/HER2- Breast Cancer (JCOG2402, Young HOPE)

NCT07671885 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

950

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Adjuvant systemic therapy based on pathological findings and ET response
DRUG: Adjuvant systemic therapy based on pathological findings

Sponsor

Tokyo Women's Medical University

Collaborators

[object Object]